Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEPOUT Rio Study
NCT07584122Recruiting
- Sponsor
- Fundação Oswaldo Cruz
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by Fundação Oswaldo Cruz. Primary endpoints: Feasibility of Community-Based PrEP Delivery at 12 months and Acceptability of Community-Based PrEP Delivery at 12 months. Started Sep 2025; status: recruiting.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07584122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584122.